Advertisement

Pathology & Oncology Research

, Volume 25, Issue 1, pp 429–435 | Cite as

Suppression of Angiotensin-(1–7) on the Disruption of Blood-Brain Barrier in Rat of Brain Glioma

  • Xiaohui Li
  • Xinjun WangEmail author
  • Jingwei Xie
  • Bo Liang
  • Jianheng Wu
Original Article

Abstract

Glioblastoma multiforme (GBM) is the most primary brain tumor, specially characterized with the damage of blood-brain barrier (BBB). The Ang-(1–7) was proven to have an inhibitory effect on glioblastoma growth. However, its role on blood–brain barrier (BBB) and the underlying molecular mechanism remains unclear. In this study, Ang-(1–7) significantly relieved the damage of blood-brain barrier in rats with intracranial U87 gliomas as evaluated by magnetic resonance imaging (MRI). Furthermore, its treatment attenuated BBB permeability, tumor growth and edema formation. Similarly, Ang-(1–7) also decreased U87 glioma cells barrier permeability in vitro. Further analysis showed that Ang-(1–7) could effectively restore tight junction protein (claudin-5 and ZO-1) expression levels both in rats and U87 glioma cells by affecting the activation of JNK pathway. SP600125, an inhibitor of JNK, significantly enhanced the expression of Claudin-5 and ZO-1, and decreased the disruption of BBB and enhanced the efficiency of Ang-(1–7) in glioma rats. Taken together, this study demonstrated a protective role of Ang-(1–7) in glioma-induced blood-brain barrier damage by regulating tight junction protein expression. Accordingly, Ang-(1–7) may become a promising therapeutic agent against glioma.

Keywords

Ang-(1–7) Glioma Blood–brain barrier Claudin-5 ZO-1 

Notes

Acknowledgments

Xiaohui Li and Xinjun Wang designed the study. Xiaohui Li, Jingwei Xie and Bo Liang performed the research and wrote the paper. Jianheng Wu performed the research. Xinjun Wang accepted full responsibility for the work.

This research was supported by the Key project of Science and Technology Research of Education Department of Henan province (14A320078).

Compliance with Ethical Standards

Disclosures

The authors have no financial conflicts of interest.

Conflicts of Interest

The authors declare no conflict of interest regarding the publication of this paper.

Ethical Approval

No.

Informed Consent

No.

References

  1. 1.
    Hawkins BT, Davis TP (2005) The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev 57(2):173–185CrossRefGoogle Scholar
  2. 2.
    Yang Y, Rosenberg GA (2011) Blood–brain barrier breakdown in acute and chronic cerebrovascular disease. Stroke 42(11):3323–3328CrossRefGoogle Scholar
  3. 3.
    Wang Z, Leng Y, Tsai L-K, Leeds P, Chuang DM (2011) Valproic acid attenuates blood–brain barrier disruption in a rat model of transient focal cerebral ischemia: the roles of HDAC and MMP-9 inhibition. J Cereb Blood Flow Metab 31(1):52–57CrossRefGoogle Scholar
  4. 4.
    Mendes B, Marques C, Carvalho I, Costa P, Martins S, Ferreira D, Sarmento B (2015) Influence of glioma cells on a new co-culture in vitro blood-brain barrier model for characterization and validation of permeability. Int J Pharm 490(1–2):94–101CrossRefGoogle Scholar
  5. 5.
    Barrier L, Fauconneau B, Noël A, Ingrand S (2010) Ceramide and related-sphingolipid levels are not altered in disease-associated brain regions of APPSL, and APPSL/PS1M146L mouse models of alzheimer's disease: relationship with the lack of neurodegeneration. Int J Alzheimers Dis 2011:920958Google Scholar
  6. 6.
    Jiao H, Wang Z, Liu Y, Wang P, Xue Y (2011) Specific role of tight junction proteins claudin-5, occludin, and ZO-1 of the blood–brain barrier in a focal cerebral ischemic insult. J Mol Neurosci 44(2):130–139CrossRefGoogle Scholar
  7. 7.
    Ferrario CM, Jessup J, Gallagher PE, Averill DB, Brosnihan KB, Ann Tallant E, Smith RD, Chappell MC (2005) Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors. Kidney Int 68(5):2189–2196CrossRefGoogle Scholar
  8. 8.
    Nishimura Y, Ito T, Saavedra JM (2000) Angiotensin II AT1 blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats. Stroke 31(10):2478–2486CrossRefGoogle Scholar
  9. 9.
    Fleegal-DeMotta MA, Doghu S, Banks WA (2009) Angiotensin II modulates BBB permeability via activation of the AT1 receptor in brain endothelial cells. J Cereb Blood Flow Metab 29(3):640–647CrossRefGoogle Scholar
  10. 10.
    Benter IF, Yousif MH, Cojocel C et al (2007) Angiotensin-(1–7) prevents diabetes-induced cardiovascular dysfunction. Am J Phys Heart Circ Phys 292(1):H666–H672Google Scholar
  11. 11.
    Weidensteiner C, Reichardt W, Shami PJ et al (2013) Effects of the nitric oxide donor JS-K on the blood-tumor barrier and on orthotopic U87 rat gliomas assessed by MRI. Nitric Oxide 30:17–25CrossRefGoogle Scholar
  12. 12.
    Patabendige A, Skinner RA, Abbott NJ (2013) Establishment of a simplified< i> in vitro</i> porcine blood–brain barrier model with high transendothelial electrical resistance. Brain Res 1521:1–15CrossRefGoogle Scholar
  13. 13.
    Amasheh S, Schmidt T, Mahn M, Florian P, Mankertz J, Tavalali S, Gitter AH, Schulzke JD, Fromm M (2005) Contribution of claudin-5 to barrier properties in tight junctions of epithelial cells. Cell Tissue Res 321(1):89–96CrossRefGoogle Scholar
  14. 14.
    Alsadi R, Ye D, Boivin M et al (2013) Interleukin-6 modulation of intestinal epithelial tight junction permeability is mediated by JNK pathway activation of claudin-2 gene. PLoS One 9(3):e85345CrossRefGoogle Scholar
  15. 15.
    Huhndorf M, Moussavi A, Kramann N, Will O, Hattermann K, Stadelmann C, Jansen O, Boretius S (2016) Alterations of the blood-brain barrier and regional perfusion in tumor development: MRI insights from a rat C6 glioma model. PLoS One 11(12):e0168174CrossRefGoogle Scholar
  16. 16.
    Subashi E, Cordero FJ, Halvorson KG et al (2016) Tumor location, but not H3.3K27M, significantly influences the blood–brain-barrier permeability in a genetic mouse model of pediatric high-grade glioma. J Neuro-Oncol 126(2):1–9CrossRefGoogle Scholar
  17. 17.
    Stegmayr C, Oliveira D, Niemietz N et al (2017) Influence of bevacizumab on blood-brain barrier permeability and O-(2-18F-fluoroethyl)-L-tyrosine uptake in rat gliomas. Eur J Nucl Med Mol Imaging 44(3):408–416CrossRefGoogle Scholar
  18. 18.
    Huang Y, Hoffman C, Rajappa P, Kim JH, Hu W, Huse J, Tang Z, Li X, Weksler B, Bromberg J, Lyden DC, Greenfield JP (2013) Oligodendrocyte progenitor cells promote neovascularization in glioma by disrupting the blood-brain barrier. Cancer Res 74(4):1011–1021CrossRefGoogle Scholar
  19. 19.
    Liu Y, Wang D, Wang H et al (2014) The protective effect of HET0016 on brain edema and blood–brain barrier dysfunction after cerebral ischemia/reperfusion. Brain Res 1544:45–53CrossRefGoogle Scholar
  20. 20.
    Zlokovic BV (2008) The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57(2):178–201CrossRefGoogle Scholar
  21. 21.
    Walter FR, Veszelka S, Pásztói M, Péterfi ZA, Tóth A, Rákhely G, Cervenak L, Ábrahám CS, Deli MA (2015) Tesmilifene modifies brain endothelial functions and opens the blood–brain/blood–glioma barrier. J Neurochem 134(6):1040–1054CrossRefGoogle Scholar
  22. 22.
    Huang Y, Hoffman C, Rajappa P, Kim JH, Hu W, Huse J, Tang Z, Li X, Weksler B, Bromberg J, Lyden DC, Greenfield JP (2014) Oligodendrocyte progenitor cells promote neovascularization in glioma by disrupting the blood-brain barrier. Cancer Res 74(4):1011–1021CrossRefGoogle Scholar
  23. 23.
    Ostergaard L, Hochberg FH, Rabinov JD et al (1999) Early changes measured by magnetic resonance imaging in cerebral blood flow, blood volume, and blood-brain barrier permeability following dexamethasone treatment in patients with brain tumors. J Neurosurg 90(2):300–305CrossRefGoogle Scholar
  24. 24.
    Higashida T, Peng C, Li J, Dornbos D, Teng K, Li X, Kinni H, Guthikonda M, Ding Y (2011) Hypoxia-inducible factor-1α contributes to brain edema after stroke by regulating aquaporins and glycerol distribution in brain. Curr Neurovasc Res 8(1):44–51CrossRefGoogle Scholar
  25. 25.
    Doolittle ND, Miner ME, Hall WA, Siegal T, Hanson EJ, Osztie E, McAllister LD, Bubalo JS, Kraemer DF, Fortin D, Nixon R, Muldoon LL, Neuwelt EA (2000) Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. Cancer 88(3):637–647CrossRefGoogle Scholar
  26. 26.
    Nitta T, Hata M, Gotoh S, Seo Y, Sasaki H, Hashimoto N, Furuse M, Tsukita S (2003) Size-selective loosening of the blood-brain barrier in claudin-5–deficient mice. J Cell Biol 161(3):653–660CrossRefGoogle Scholar
  27. 27.
    Rodgers LS, Beam MT, Anderson JM, Fanning AS (2013) Epithelial barrier assembly requires coordinated activity of multiple domains of the tight junction protein ZO-1. J Cell Sci 126(7):1565–1575CrossRefGoogle Scholar
  28. 28.
    Koto T, Takubo K, Ishida S, Shinoda H, Inoue M, Tsubota K, Okada Y, Ikeda E (2007) Hypoxia disrupts the barrier function of neural blood vessels through changes in the expression of claudin-5 in endothelial cells. Am J Pathol 170(4):1389–1397CrossRefGoogle Scholar
  29. 29.
    Chen D, Wei XT, Guan JH, Yuan JW, Peng YT, Song L, Liu YH (2012) Inhibition of c-Jun N-terminal kinase prevents blood-brain barrier disruption and normalizes the expression of tight junction proteins clautin-5 and ZO-1 in a rat model of subarachnoid hemorrhage. Acta Neurochir 154(8):1469–1476CrossRefGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2018

Authors and Affiliations

  1. 1.Department of NeurosurgeryThe Fifth Affiliated Hospital of Zhengzhou UniversityZhengzhouChina

Personalised recommendations